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Abstract
Background: Alzheimer’s disease (AD)-linked β-amyloid (Aβ) accumulates in multivesicular bodies (MVBs) with the
onset of AD pathogenesis. Alterations in endosomes are among the earliest changes associated with AD but the
mechanism(s) that cause endosome enlargement and the effects of MVB dysfunction on Aβ accumulation and tau
pathology are incompletely understood.
Methods: MVB size and Aβ fibrils in primary neurons were visualized by electron microscopy and confocal
fluorescent microscopy. MVB-dysfunction, modelled by expression of dominant negative VPS4A (dnVPS4A), was
analysed by biochemical methods and exosome isolation.
Results: Here we show that AD transgenic neurons have enlarged MVBs compared to wild type neurons.
Uptake of exogenous Aβ also leads to enlarged MVBs in wild type neurons and generates fibril-like structures
in endocytic vesicles. With time fibrillar oligomers/fibrils can extend out of the endocytic vesicles and are
eventually detectable extracellularly. Further, endosomal sorting complexes required for transport (ESCRT)
components were found associated with amyloid plaques in AD transgenic mice. The phenotypes previously
reported in AD transgenic neurons, with net increased intracellular levels and reduced secretion of Aβ, were
mimicked by blocking recycling of ESCRT-III by dnVPS4A. DnVPS4A further resembled AD pathology by
increasing tau phosphorylation at serine 396 and increasing markers of autophagy.
Conclusions: We demonstrate that Aβ leads to MVB enlargement and that amyloid fibres can form within
the endocytic pathway of neurons. These results are consistent with the scenario of the endosome-lysosome
system representing the site of initiation of Aβ aggregation. In turn, a dominant negative form of the
CHMP2B-interacting protein VPS4A, which alters MVBs, leads to accumulation and aggregation of Aβ as well
as tau phosphorylation, mimicking the cellular changes in AD.
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Background
Alzheimer’s disease (AD) is characterized by progressive
decline in cognitive function, anatomical selective loss of
synapses and neurons, and aggregation of the β-amyloid
peptide (Aβ) in amyloid plaques and hyperphosphorylated
tau in neurofibrillary tangles (NFTs). Although plaques
are extracellular aggregates of Aβ, accumulation of Aβ42,
the most pathogenic Aβ peptide, begins within neurons in
AD [1–3] and in AD transgenic mouse models [4–6]. In
AD transgenic mice, cognitive, physiological and struc-
tural impairments appear prior to plaques [7–9] and are
accompanied by intraneuronal Aβ peptide accumulation,
supporting that accumulation of intraneuronal Aβ pep-
tides is one of the earliest events in AD pathogenesis [10].
Abnormalities in the endocytic pathway are also among
the earliest pathological features reported in AD, preced-
ing the classical pathological markers of Aβ plaques and
NFTs [11]. Specifically, enlargement of Rab5-positive early
endosomes and Rab7-positive late endosomes were re-
ported in AD [12, 13], as well as progressive accumulation
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of multivesicular bodies (MVBs), lysosomes and autopha-
gic vacuoles [14]. The amyloidogenic cleavage of APP oc-
curs predominantly in endosomes [15–19]. Proteins in the
amyloidogenic pathway (APP, the β-site APP cleaving en-
zyme (BACE1) and the γ-secretase that generates the Aβ
peptides) are transmembrane proteins that traffic through
the secretory pathway as well as the endocytic pathway.
Immuno-electron microscopy revealed that particularly
the limiting membrane of MVBs are the normal location
of Aβ42 in neurons of the brain and are the sites of Aβ ac-
cumulation during AD pathogenesis [20], especially at
synapses [5]. Sorting of EGFR via the MVB pathway was
impaired by endosomal Aβ accumulation in cultured AD
transgenic neurons [21]. Translocation into MVBs ap-
peared particularly affected, suggesting Aβ dependent dys-
function of the late endosomal sorting complexes required
for transport (ESCRT) pathway in AD.
The ESCRTs are a set of proteins conserved from yeast
to mammals that regulate and drive formation of the intra-
luminal vesicles of MVBs. They assemble into distinct sub-
complexes: ESCRT-0, ESCRT-I, ESCRT-II and ESCRT-III.
Their sequential action directs the sorting of ubiquitinated
transmembrane proteins and the inward budding of intra-
luminal vesicles (ILVs) into the lumen of endosomes,
thereby generating MVBs that then either deliver
membrane-associated cargo to the lysosome for degrad-
ation, release the intraluminal vesicles (then called exo-
somes) via fusion with the plasma membrane or traffic
cargo back to the Golgi apparatus. ESCRT-III subunits,
among them CHMP2B, are inactive monomers in the cyto-
plasm [22] that assemble on endosomal membranes in an
ordered manner to generate the transient ESCRT-III com-
plex. CHMP2B, linked genetically to frontotemporal de-
mentia (FTD) and AD [23, 24], directly interacts with and
recruits the VPS4 AAA–ATPase complex that disassembles
ESCRT-III, and genome-wide association studies for late
onset AD identified an association with VPS4B [25].
Given the cumulative genetic, biological and patho-
logical evidence implicating Aβ in AD, and the early accu-
mulation of Aβ in MVBs in AD, we set out to test our first
hypothesis (1) that Aβ can cause the abnormal endosomal
phenotype seen in AD. To determine this, we investigated
the effects of Aβ on MVB size and Aβ aggregation in late
endosomes. Since Aβ accumulates particularly at the outer
limiting membrane of MVBs where ESCRTs reside and
since ESCRT dysfunction leads to endosomal enlargement
we also tested our second hypothesis (2) that Aβ causes
dysfunction of the ESCRT pathway. This was investigated
by examining changes in ESCRT proteins in primary neu-
rons, as well as modulating the late ESCRT pathway to
examine how this influences Aβ accumulation.
Here we provide experimental evidence of Aβ-dependent
MVB enlargement as well as Aβ aggregation within late
endocytic compartments of neurons. Consistent with the
scenario of MVBs representing the site of initiation of Aβ
aggregation, the accumulation of neuronal ESCRT compo-
nents was evident in amyloid plaques. Moreover, dysfunc-
tion of ESCRT-III, modelled by dominant negative VPS4A
(dnVPS4A) mimicked the Aβ accumulation and aggrega-
tion in MVBs as well as the enlarged late endosomal size
seen in AD. These results support a novel scenario where a
vicious cycle of ESCRT-dependent late endosomal dysfunc-
tion causes further Aβ accumulation as well as AD-
pathogenic tau phosphorylation.
Methods
Cell culture
Primary neuronal cultures were generated from B6.Cg-Tg
(APPswe, PSEN1dE9)85Dbo/Mmjax mice (APP/PS1) AD
transgenic (tg) and wild-type (wt) mouse embryos. The
APP sequence in APP/PS1 encodes a chimeric mouse/hu-
man APP (Mo/HuAPP695swe) that was humanized by
modifying three amino acids, and introducing the Swedish
AD mutation. The PS1 sequence encodes human presenilin
1 lacking exon 9 (dE9) that models AD-associated muta-
tions in PS1. Both APPswe and PS1 are independently con-
trolled by the prion protein promoter. Primary neuronal
cultures were prepared from cortices and hippocampi of
embryonic day 15 embryos as previously described [9]. In
brief, E15 brain tissue was dissociated by trypsinization and
trituration in DMEM with 10% fetal bovine serum (Gibco).
Dissociated neurons were cultured on poly-D-lysine
(Sigma) coated plates or glass coverslips (Bellco Glass Inc.)
and were maintained until 12 and 19 DIV in neurobasal
medium (Gibco), B27 supplement (Gibco), glutamine (Invi-
trogen) and antibiotics (ThermoScientific).
Wild type mouse N2a neuroblastoma cells (N2a) or N2a
cells stably transfected with the 670/671 Swedish mutation
human APP (Swe) [26] or wild-type α-synuclein with HA-
Tag (α-syn) were grown on 10 cm dishes or coverslips.
Electron microscopy
Cells were grown on Thermanox coverslips (Nalgene,
Nunc) and fixed with 2% PFA, 2.5% glutaraldehyde in
0.1 M cacodylate. Cells were then secondarily fixed with 1%
osmium tetroxide followed by incubation with 1% tannic
acid to enhance contrast. Cells were dehydrated using in-
creasing percentages of ethanol before being embedded
onto Epoxy resin (Agar scientific, UK) stubs. Coverslips
were cured overnight at 65 °C. Ultrathin sections were cut
using a diamond knife mounted to a Reichert ultracut S ul-
tramicrotome and sections were collected onto copper
grids. Grids were post-stained with drops of lead citrate.
Sections were viewed on a FEI Tecnai transmission elec-
tron microscope (Eindhoven, The Netherlands) at a work-
ing voltage of 80 kV. BSA-gold was prepared as previously
described [27]. For quantification of MVB diameter, MVBs
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were defined as organelles containing intraluminal vesicles
and monomeric rather than flocculated BSA-gold.
Aβ1-42 peptides (Sigma) were incubated at 37 °C for
1 h to induce fibril formation in vitro. Grids were
inverted onto the drops of Aβ1-42, negatively stained
with 2% uranyl acetate, washed with water and dried on
filter paper before being viewed by EM.
Transfection and constructs
Cells were transfected using Lipofectamine 2000 (Invitro-
gen) for N2a cells or Lipofectamine 3000 (Invitrogen) for
primary neurons. N2a cells were transfected in Opti-MEM
while primary neurons were transfected directly in their
growth medium. The plasmids p3xFLAG-CMV-10-
hVPS4A-wt and p3xFLAG-CMV-10-hVPS4A-dn E228Q
were generated as described [28]. The control plasmids
p3xFLAG-CMV-7-BAP Control Plasmid was purchased
from Sigma-Aldrich and pcDNA3-CMV-GFP from
Addgene. pcDNA3-synapsin-FLAG-wtVPS4 and pcDNA3-
synapsin-FLAG-dnVPS4 were constructed from pcDNA3-
synapsin-FLAG and PCR products from the p3xFLAG-
CMV-10-hVPS4A-wt and p3xFLAG-CMV-10-hVPS4A-dn
respectively. Control plasmid pAAV-synapsin-GFP was
purchased from Addgene.
Antibodies and reagents
The following antibodies were used (see also Additional file
1: Table S1): 369 [29] (Buxbaum et al., 1990) for Western
blot (WB) 1:1000; 6E10 (BioLegend, previously Covance
SIG-39320) IF: 1:500, WB 1:1000; 12F4 (BioLegend, previ-
ously Covance SIG-39142) for immunofluorescence (IF)
1:250; Amyloidβ (1-42) (IBL, 18,582); Amyloidβ (1-42)
(Invitrogen, 700,254) IF 1:1000; beta-actin (Sigma, A 5316)
WB 1:2000; CD63 (ThermoFisher Scientific, MAI-19281)
WB 1:1000; CHMP2B (Abcam, ab33174) IF 1:250, WB
1:1000; Clavestin-1 + 2 (Bioss, bs-6569R-A647) IF 1:250;
DAPI (Sigma, D9542) IF 1:2000; drebrin (Abcam, ab11068)
IF 1:1000; FLAG (Biolegend, 637,302) IF 1:1000, (Sigma,
F1804) WB 1:1000; Flotillin-1 (BD Biosciences, 610,821) IF
1:400; GM130 (BD Biosciences, 610,822) IF: 1:500; GSK3β
(Cell Signaling Technology, 12,456) IF 1:400; pGSKα/β (Cell
Signaling Technology, 9331S) WB 1:1000; HA-Tag (Cell
Signaling Technology, 3724) WB 1:1000; Hrs and Hrs-2
(Enzo, ALX-804-382-C050) IF 1:100; LAMP1 (Abcam,
ab24170) IF 1:1000; LAMP1 (Abcam, ab25245) IF: 1:1500;
LC3β (Cell Signaling Technology, 2775) WB 1:1000; Amyl-
oid fibrils OC (Merck Millipore, AB2286) IF 1:1000; P2:1
(ThermoFisher Scientific, OMA1-03132) IF 1:500;
Phospho-tau pSer396 (ThermoFisher, 44-752G); Rab7
(Abcam, ab50533) IF 1:500; Synaptophysin (Merck Milli-
pore, MAB5258) IF 1:1000; Tsg101 (Genetex, GTX70255)
IF 1:250, WB 1:1000; VPS4 (SantaCruz, sc-133,122) IF
1:100, WB 1:1000; secondary antibodies conjugated to Alexa
Fluor-488, −546, −647 (IF 1:500; Invitrogen) or to HRP
(WB 1:2000; R&D Systems, Minneapolis, MN).
Bafilomycin A (Sigma), torin 1 (Tocris) or rapamycin
(Fisher BioReagents) were added to pre-warmed culture
media at appropriate concentrations. Starvation media
for induction of autophagy was 33% Opti-MEM in
Hank’s Balance Salt solution (HBSS). Aβ1-40 or Aβ1-42
peptides (Tocris) were reconstituted in DMSO to
250 μM, sonicated for 10 min and followed by 15 min of
centrifugation at 12 k rpm before adding the supernatant
to the culture media for the depicted times. All experi-
ments used 0.5 μM of Aβ1-40 or Aβ1-42, except for EM
and LAMP-1 positive vesicle size experiments that used
5 μM and 1 μM respectively.
Cell immunofluorescence
Cultured neurons at 12 DIV or N2a cells were fixed in 4%
paraformaldehyde (PFA) in phosphate buffered saline
(PBS) with 0.12 M sucrose for 20 min, permeabilized and
blocked in PBS containing 2% normal goat serum (NGS),
1% bovine serum albumin (BSA), and 0.1% saponin at
room temperature (RT) for 1 h, and then immunolabelled
in 2% NGS in PBS overnight at 4 °C. After appropriate
washing, coverslips were mounted with SlowfadeGold
(Invitrogen). Immunofluorescence was examined by con-
focal laser scanning microscopy (Leica TCS SP8 or Zeiss
LSM 510). In multiple label experiments, channels were
imaged sequentially to avoid bleed-through. Images were
taken with Leica Confocal Software or Zeiss ZEN software
and analysed with ImageJ or Imaris 7.6. LAMP1-positive
vesicles in pyramidal neurons were quantified by measur-
ing the diameter of the five largest LAMP1-positive vesi-
cles per cell, imaged by confocal microscopy in z-stacks,
(n= >45 LAMP1-positive vesicles). All fluorescent label-
ling of cells was performed n ≥ 3; and in the case of pri-
mary neurons from different embryos.
Brain immunofluorescence
Mice were anesthetized with isoflurane and perfused trans-
cardially with saline followed by 4% PFA in 0.1 M PBS
(pH 7.4) at RT. After dissection, brains were postfixed by
immersion in 4% PFA in 0.1 M PBS (pH 7.4) at 4 °C for 2 h
or overnight. After fixation, brains were cut in 40 μm thick
sections with a sliding microtome. Sections were kept in
storage buffer composed of 30% sucrose and 30% ethylene
glycol in PBS at −20 °C. Free-floating sections were blocked
for 1 h in RT with serum and triton-X and then incubated
in primary antibodies overnight at 4 °C, followed by appro-
priate fluorescent Alexa secondary antibodies for 1 h at RT.
Western blot
Medium was collected and centrifuged and cells were
washed twice, harvested in ice cold PBS, and centrifuged.
Cell pellets were lysed with 6% sodium dodecyl sulfate
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(SDS) containing 10 μl/ml β-mercaptoethanol, sonicated,
and then heated at 95 °C for 6 min. After centrifugation, su-
pernatants and medium were mixed with loading buffer,
heated at 95 °C for 5 min and loaded into 10–20% Tricine
gels (Invitrogen). Samples were subjected to electrophoresis
and transferred to polyvinylidine difluoride membranes
(Millipore). Membranes were blocked in PBS containing
0.1% Tween-20 (PBST) and 5% milk, and incubated in pri-
mary antibodies overnight and then with HRP-conjugated
secondary antibodies for 1 h diluted in PBS containing 0.1%
Tween-20 (PBST) and 5% milk. The immunoreaction was
visualized by a chemiluminescence system (Pierce or
BioRad). Bands were quantified using Image Lab (Bio-Rad
Laboratories). For visualization of Aβ, membranes were
boiled in PBS for 5 min prior to blocking. For analysis of
exosomes, WB was performed as above but without β-
mercaptoethanol in the 6% SDS lysis buffer.
For analysis of LC3β cells were lysed in RIPA buffer
(Thermo Fisher Scientific) with protease inhibitor and
phosphatase inhibitor (Thermo Fisher Scientific). Lysates
with NuPAGE LDS sample buffer and NuPAGE redu-
cing agent were loaded on NuPAGE 4-12% BisTris gels
and run with NuPAGE MES SDS buffer (Invitrogen).
For analysis of α-synuclein in medium, total protein was
extracted using a trichloroacetic acid (TCA)/acetone pre-
cipitation protocol. Briefly, freshly collected samples were
cleared by centrifugation at 10000 rpm for 10 min to pel-
let debris and intact cells. The supernatant was transferred
to a new tube and added with ¼ volume of ice-cold 20%
TCA followed by incubation on ice for 3 h. The proteins
were pelleted by centrifugation at 14000 rpm and washed
twice with cold acetone.
For native conditions, cell pellets were lysed on ice in
NativePAGE sample buffer (1X, Life Technologies) con-
taining 1% digitonin (Life Technologies) and Halt pro-
teinase inhibitor cocktail (1X, Thermo Scientific) by
pipetting up and down and incubating on ice for 15 min.
Lysates were centrifuged at 20000 x g for 30 min at 4 °C
and protein concentrations of the supernatants were de-
termined with BCA assay. Equal amounts of protein
were loaded on a 3-12% NativePAGE Novex Bis-Tris gel
(Life Technologies).
Exosome isolation and analysis
Exosomes were purified from cell culture medium by
differential ultracentrifugation as described previously
[30]. Briefly, Swe N2a cells were cultured and trans-
fected for 48 h in exosome-free medium. Collected
medium was depleted of cells and cellular debris by
sequential low speed centrifugation. Exosomes were
then isolated by centrifugation of the collected super-
natant at 100,000×g at 4 °C for 70 min. The resultant
pellet was washed in PBS and centrifuged for 70 min
at 100,000×g at 4 °C.
Statistical analysis
Statistical analysis was performed with PRISM 6 soft-
ware (Graph-Pad Software, San Diego, CA, USA) by
using unpaired t-test or ANOVA with Tukey’s multiple
comparisons test or ANOVA with Dunnett’s multiple
comparisons test. All data are expressed as the
mean ± SD. Differences were considered significant at
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Results
Aβ-dependent MVB enlargement
Endogenous Aβ42 is present in both dendrites and axons
of cultured primary APP transgenic neurons and localizes
especially with markers of late endosomes/MVBs [21]. In
order to examine whether increased levels of Aβ can lead
to the enlarged endosomal phenotype seen in AD, MVB
size was compared between APP/PS1 transgenic and wt
primary mouse neurons. Cells were incubated with BSA-
gold 2 h (h) before fixation to confirm identity of the
endocytic compartments. Remarkably, electron micro-
graphs showed a significantly greater MVB diameter (52%
increase; p < 0.001) in APP/PS1 transgenic compared to
wt neurons at 12 days in vitro (DIV) (Fig. 1a and b) con-
sistent with the larger diameter of endosomes described in
human AD. Since full length APP, β-CTFs, Aβ and the
presenilin mutation in the APP/PS1 transgenic neurons
potentially all could be the cause of this effect, wt neurons
at 12 DIV were treated with freshly prepared human syn-
thetic Aβ1-40 or Aβ1-42 for 48 h, to test if Aβ was suffi-
cient to induce the endosomal enlargements. The neurons
demonstrated a 69% and 114% increase in the diameter of
MVBs with Aβ1-40 or Aβ1-42 treatment, respectively
(p < 0.001; Fig. 1c and d) as measured on EM images com-
pared to controls. Further, an increased size by 165% of
LAMP1-positive late endosomes/lysosomes was already
evident by immunofluorescent labelling at 3 h in pyram-
idal neurons treated with Aβ1-42 (p < 0.0001, Fig. 1e and
f). LAMP1-changes at different time points of Aβ1-42
treatment, ranging from 30 s to 48 h, are shown in Add-
itional file 2: Figure S1B. Taken together, our results indi-
cate that enlarged MVBs, one of the earliest pathological
features in AD, can be caused by Aβ, which however does
not rule out important contributions also of other APP
components such as β-CTFs.
Fibril-like structures in endocytic organelles of wild-type
neurons treated with Aβ
Interestingly, fibril-like structures were apparent by EM in
endocytic organelles of wt primary neurons incubated
with synthetic human Aβ1-42 for 48 h that were not seen
in untreated neurons (Fig. 2a), and were more prominent
in neurons treated with Aβ1-42 than Aβ1-40. For com-
parison, Aβ1-42 fibrilized in vitro showed similar size and
morphology of fibrils on EM as in the endocytic vesicles
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(Fig. 2b). Loss of endolysosomal impermeability was also
seen with Aβ1-42 treatment of neurons with BSA-gold
leaking out into the cytoplasm (Fig. 2c). To further investi-
gate the fibril-like structures, wt murine neurons were
treated with elevated levels of human Aβ1-42 at different
time points and immunolabelled with the conformational
dependent Aβ antibody OC to label amyloid fibrils and fi-
brillar oligomers [31] and antibody 6E10 to specifically
label the added human Aβ. Using the same parameters as
in the EM experiments, neurons treated with Aβ1-40 only
led to weak OC antibody labelling compared to vehicle
treated cells, while Aβ1-42 treated neurons showed robust
OC labelling (Additional file 3: Figure S2).
Already at 45 min of treatment with 0.5 μM Aβ1-42 (Fig.
2d) and up to 24 h of incubation, antibodies OC and 6E10
revealed an almost completely overlapping vesicular pattern
of labelling, indicating that the amyloid fibrils and/or fibril-
lar oligomers consisted of Aβ1-42, which was particularly
prominent along neuronal processes. Of note, OC labelling
increased in intensity with time of treatment with Aβ1-42.
Interestingly, at 48 h the OC positive structures were en-
larged and elongated, displaying a part that was human Aβ
antibody 6E10 positive and an extension that was 6E10
negative (Fig. 2e). Surface labelling of non-permeabilized
cells revealed that the elongated OC labelling at 48 h was
now to a certain extent extracellular, whereas the punctate
OC and 6E10 co-labelling at 24 h was generally intracellular
(Fig. 2f). This suggests that with time, fibrils extend out of
neurites into the extracellular space and/or that organelles
containing the fibrils fuse with the plasma membrane. To
better define the subcellular site of Aβ aggregation, cells
were double labelled with OC antibody and the late endo-
somal/lysosomal marker LAMP1. At 45 min colocalization
with OC was evident in small LAMP1-positive vesicles in
the processes but not in the larger LAMP1-positive vesicles
in the cell soma (Additional file 4: Figure S3A). Since lyso-
somes normally do not localize to axons and dendrites,
other than their very proximal part, this suggests that Aβ42
starts to aggregate in late endosomes/MVBs of neurites. At
48 h, OC and LAMP1 still colocalized mainly in neuronal
processes, but in LAMP1-positive structures that now ap-
peared somewhat enlarged and irregular in their shape.
Elongated OC-positive structures could be seen extending
out from the more punctate LAMP1 labelling (Fig. 2g and
Additional file 4: Figure S3A). The late endosomal marker
Rab7 indicated that at least a subset of the vesicular OC la-
belling at 24 h colocalized with Rab7 positive late endocytic
compartments in neurites (Additional file 4: Figure S3C).
Taken together these data indicate that Aβ1-42 can be
taken up by neurons in culture and forms amyloidogenic
fibrils and/or fibrillar oligomers in late endocytic compart-
ments particularly within neuronal processes that eventu-
ally appear to extend extracellularly.
Aβ1-42 induces changes in the native state of ESCRT-III
complex component CHMP2B
Given prior evidence supporting that sorting via the MVB
pathway was impaired by Aβ accumulation in cultured AD
transgenic neurons and that Aβ dependent translocation
into MVBs seemed affected [21], we next investigated pos-
sible dysfunction of the ESCRT pathway in models of AD.
In APP/PS1 transgenic primary neurons Aβ42 was found
associated with CHMP2B-positive vesicles (Fig. 3a). In
young 3-month-old Tg19959 mice, a different transgenic
mouse model of β-amyloidosis harbouring the Swedish and
Indiana APP mutations, CHMP2B immunolabelling was
most prominent in the area of hippocampus and entorhinal
cortex that also expressed increased levels of Aβ/APP
(Additional file 5: Figure S4A-B). Although levels of total
CHMP2B and VPS4 were not significantly changed in wt
compared to APP/PS1 primary neurons lysed in 6% SDS
(Additional file 5: Figure S4C), levels of high molecular
weight complexes of CHMP2B on blue native polyacryl-
amide gel electrophoresis were increased in APP/PS1 neu-
rons treated with Aβ1-42 for 3 h (Fig. 3b). Other ESCRT
proteins were not resolved on native gels, likely due to
masking of antibody epitopes under native conditions.
ESCRT components localize to amyloid plaques
Since AD transgenic neurons showed an increased diam-
eter of MVBs and treatment with Aβ1-42 led to promin-
ent fibril-like structures in late endocytic organelles, and
as prior immuno-EM work has indicated early Aβ accu-
mulation in dystrophic neurites [10], we next examined
whether aggregating Aβ42 in endosomes might lead to
the presence of ESCRT components in amyloid plaques.
Indeed, APP/PS1 transgenic mice with plaque pathology
demonstrated that the ESCRT-III associated protein VPS4
(See figure on previous page.)
Fig. 1 Aβ increases MVB diameter in primary neurons. a Electron microscopy reveals that APP/PS1 AD transgenic compared to wt mouse primary
neurons have significantly larger MVBs at 12 DIV. Scale bar 500 nm. b Quantification of A shows an increase of 52% in MVB diameter in Tg
compared to wt neurons, n > 94 MVBs per group; *** p < 0.001. c Exogenously added monomeric Aβ1-40 or Aβ1-42 to wt primary neurons at 12
DIV leads to increased MVB diameter at 48 h on EM images. MVBs are marked with an asterisk. Scale bar 500 nm. d Quantification of C, n > 45
MVBs per group; *** p < 0.001. e Shorter time-points of exogenously added monomeric Aβ1-42 already leads to increased size of LAMP1-positive
vesicles 3 h after treatment in wt mouse neurons at 12 DIV; 3D-rendering with Imaris from confocal z-stack. High magnification image of LAMP1
labelling from a single focal plane to the right. Scale bar 10 μm. f Quantification of E shows significant increase in diameter of LAMP1-positive
vesicles after addition of Aβ. The diameters of the five largest LAMP1-positive vesicles per pyramidal neuron were measured in the z-stacks;
n > 10 neurons per treatment; **** p < 0.0001
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was markedly increased in plaques (Fig. 3c and Additional
file 5: Figure S4D), where it partially colocalized with
Aβ42. ESCRT–I component Tsg101, a marker of MVBs,
also showed increased labelling in plaques (Fig. 3d). In
contrast, labelling of CHMP2B and the earlier ESCRT-0
component Hrs appeared decreased in plaques compared
to surrounding brain parenchyma (Additional file 5: Fig-
ure S4E-F). Brain sections were also co-labelled with an
antibody against clavestin-1 and 2 (Fig. 3d), which are
neuron-specific proteins in the endo-lysosomal pathway
[32]. The strong colocalization between Tsg101 and
clavesin-1 and 2 in amyloid plaques supports the neuronal
origin of ESCRT components in plaques. Moreover, much
of the strong Aβ42 labelling outside of plaques in AD
transgenic brain occurred in vesicle-like structures of dys-
trophic neurites that also contained clavesin-1 and 2 and
Tsg101, consistent with accumulation of Aβ42 within
endosomal compartments of neurons. To confirm these
results in a different AD transgenic mouse model of β-
amyloidosis, Tg19959 mice were examined with the onset
of plaque pathology. In early plaques of 3-month-old
Tg19959 mice Tsg101 (Fig. 3e) and VPS4 (not shown) also
colocalized strongly with Aβ42.
Blocking VPS4A increases intracellular accumulation and
decreases secretion of Aβ
In order to model the effect of dysfunctional ESCRT-
dependent MVBs on Aβ accumulation, a dominant nega-
tive, E228Q ATPase-deficient form of VPS4A (dnVPS4A)
was expressed for 24 h in N2a neuroblastoma cells har-
bouring stably transfected human Swedish mutant APP.
N2a cells were used here because of their high transfec-
tion efficiency compared to primary neurons. To assess
that N2a cells react to Aβ1-42 in a similar manner as pri-
mary neurons, N2a cells were treated with exogenously
added Aβ1-42 for different time points. N2a cells treated
with Aβ1-42 also exhibited increased size of LAMP1-
positive vesicles (Additional file 6: Figure S5). The ATPase
VPS4 is a key component of the ESCRT machinery as it is
the only energy-consuming enzyme, promotes disassem-
bly and recycling of ESCRT-III oligomers, and is recruited
to the ESCRT-III complex by direct interaction with
CHMP2B. We found that the expression of dnVPS4A
markedly increased the intracellular pool of Aβ by 424%
(p < 0.001, Fig. 4a and d) while concurrently decreasing
the amounts of Aβ secreted into the medium by 87%
(p < 0.0001, Fig. 4c and d). DnVPS4A also increased
higher molecular weight bands between 17 kDa and
34 kDa that might represent Aβ oligomers within cells
(Fig. 4a) as they were not seen with C-terminal specific
APP antibody 369 (Fig. 4b). In addition, dnVPS4A in-
creased the levels of APP within cells by 149% (p < 0.05)
and secreted APPα in conditioned media by 149%
(p < 0.05). Overexpression of wild type VPS4A (wtVPS4A)
also significantly reduced secretion of Aβ by 72%
(p < 0.001), although not to the extent of the dominant
negative construct. Such a partially dominant negative ef-
fect of over-expressing wtVPS4 has been described [28].
Confocal immunofluorescence microscopy of Swe N2a
cells transfected with dnVPS4A confirmed the increase
of Aβ and full-length APP (Fig. 4e). Increased labelling
by immunofluorescent microscopy with the conform-
ational antibody OC in dnVPS4A-transfected cells con-
firmed the increase in Aβ oligomers and showed that
the fibrillar oligomers and/or fibrils labelled by antibody
OC colocalized with enlarged vesicles labelled positive
for dnVPS4A protein and flotillin-1 (Fig. 4f and g).
Triple labelling revealed that Aβ42 accumulated in en-
larged vesicles positive for the MVB marker Tsg101 in
dnVPS4A expressing cells labelled by the FLAG-tag (Fig.
4h). Thus, dysfunctional MVBs accumulate Aβ42 that,
at least in part, is in an oligomeric and/or fibrillar
form. In contrast to effects on Aβ and in agreement
with a prior report [28], dnVPS4A increased secretion
of α-synuclein in α-syn N2a cells without altering the
total pool of intracellular α-synuclein (Additional file
(See figure on previous page.)
Fig. 2 Fibril-like structures in endocytic organelles of wild-type neurons treated with Aβ1-42. a Wt primary neurons treated at 12 DIV with
Aβ for 48 h induced fibril-like structures in endocytic organelles with Aβ1-42. BSA-gold was added to cells 2 h before fixation to delineate
endocytic organelles (marked with asterisk). Scale bar 500 nm. High magnification image to the right, scale bar 100 nm. b Aβ1-42 peptides
incubated in vitro at 37 °C for 1 h to induce fibril formation, imaged with EM. Scale bar 100 nm. c BSA-gold (white arrows) was found in the
cytosol in Aβ1-42 treated neurons, indicating loss of endolysosomal impermeability due to Aβ1-42. Scale bar 500 nm. d OC antibody labelling
for fibrillar oligomers and/or fibrils is seen in a vesicular pattern in processes after 45 min treatment with 0.5 μM of Aβ1-42 and colocalizes
with human Aβ antibody 6E10 confirming that fibrils consist of the added human Aβ1-42. Scale bar 10 μm. e Feeding 0.5 μM of Aβ1-42 to wt
primary neurons at 12 DIV at 24 h vs 48 h. At 24 h most of the OC labelling was also antibody 6E10 positive. At 48 h the outer aspects of OC
positive structures were 6E10 negative. Scale bar 20 μm. f Weak surface labelling of non-permeabilized neurons shows that OC and 6E10
antibody positive structures were intracellular after 24 h of treatment with Aβ1-42 (upper panel). At 48 h extracellular OC antibody labelling
was now more visible consistent with penetration of the plasma membrane by the elongated OC positive fibrils (middle panel). Strong OC and
6E10 antibody labelling of permeabilized cells after fixation but before immunolabelling, shows that the vast majority of added human Aβ1-42
(antibody 6E10) and OC antibody positive fibrils and/or fibrillar oligomers are inside neurons (lower panel). Scale bar 20 μm. g After 48 h of
treatment with 0.5 μM Aβ1-42, OC antibody labelling was seen extending out from LAMP1-positive structures in the processes. The image
shows OC with the superimposed colocalizing channel for LAMP1 and OC. For the complete image with separate channels see Additional file 3: S2A.
Scale bar 20 μm
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7: Figure S6). Since the CMV-FLAG-dnVPS4A in-
duced toxicity in primary neurons, we constructed a
plasmid under the weaker synapsin promoter. Ex-
pressing dnVPS4A under this synapsin promoter in
wt or APP/PS1 primary neurons showed increased la-
belling of Aβ42 (Fig. 4i), supporting that dysfunctional
ESCRT-dependent MVB formation leads to increased
levels of Aβ within neurons.
a b
c
d
e
Fig. 3 Aβ42 increases high molecular weight complexes of CHMP2B and ESCRT proteins accumulate in amyloid plaques. a Immunolabelling of
APP/PS1 transgenic primary neurons shows Aβ42 colocalizing with CHMP2B-positive vesicles. Scale bar 10 μm, n = 3. b A trend for increased high
molecular weight complexes of CHMP2B, a 24 kDa ESCRT-III component, in APP/PS1 transgenic compared to wt neurons is seen on native gel.
Treatment with 0.5 μM of Aβ1-42 for 3 h further increases these high molecular weight complexes. However only APP/PS1 transgenic neurons
treated with Aβ1-42 show a statistically significant increase in high molecular weight complexes compared to wt. Equal amounts of total protein
were loaded into the wells, n = 6; *p < 0.05. c VPS4 colocalizes with Aβ42 in amyloid plaques of 19-month-old APP/PS1 mice. Scale bar 40 μm,
n = 4. d Tsg101 colocalizes with both Aβ42 and the neuronal-specific endo-lysosomal marker clavesin 1 and 2 in amyloid plaques of 19-month-old
APP/PS1 mice. Scale bar 40 μm, n = 3. e In early plaques present in the 3-month-old Tg19959 mice Tsg101 also colocalized with Aβ42. Scale bar
40 μm, n = 3
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Fig. 4 (See legend on next page.)
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Increased cellular levels of Aβ with dysfunctional MVBs is
mimicked by inhibiting lysosomal degradation
The increased intracellular levels of Aβ with
dnVPS4A could be due to changes in the production
of Aβ, reduced secretion and/or reduced fusion of
MVBs with the lysosome for degradation. In order to
investigate the turnover of APP and Aβ, Swe N2a
were treated with the protein synthesis inhibitor cy-
cloheximide (Additional file 8: Figure S7A-B and
Additional file 9: Figure S8D). This revealed a rapid
turnover of APP in cell lysates with a half-life of
about 45 min, while cellular Aβ had a half-life of
about 4 h. In contrast, the degradation of APP and
Aβ in conditioned media was slower, not reaching
50% of control levels within 6 h of cycloheximide
treatment. To investigate the role of lysosomal deg-
radation, Swe N2a cells were treated for 24 h with
5 nM bafilomycin A1 (BafA1), which inhibits the
vacuolar H+ ATPase. BafA1 treatment had the same
effects on Aβ as dnVPS4A, markedly increasing intra-
cellular levels of Aβ and reducing the secretion of Aβ
(Fig. 5a-b and Additional file 9: Figure S8A-D). These
results suggest that dnVPS4A blocks MVBs with Aβ
on route to lysosomes for degradation. Consistently,
when the endo-lysosomal pH gradient was blocked
with BafA1, dnVPS4A transfected cells no longer
showed higher cellular levels of Aβ than the wtVPS4A
or GFP transfected cells (Fig. 5c). Hence, when the
ability of lysosomes to degrade Aβ is abolished, block-
ing Aβ on route to the lysosomes via dnVPS4 does
not lead to further Aβ accumulation.
To investigate the secretion of Aβ via fusion of MVBs
with the plasma membrane and concomitant release of
exosomes, exosomes from dnVPS4A-transfected Swe
N2a cells were isolated and analysed (Fig. 5d). Secretion
of exosomes was not prevented but instead increased by
dnVPS4A in Swe N2a cells, possibly due to upregulation
of ESCRT independent (CD63 dependent) MVB forma-
tion [33–35].
Blocking ESCRT dependent ILV formation increases
pathological tau phosphorylation
A major question in AD is how Aβ links to tau pathology.
MVBs are necessary for the sequestration of GSK3 [36]
which phosphorylates tau at serine 396 (S396). Both ele-
vated tau phosphorylation at S396 [37] and hyperactive
GSK3 is implicated in AD [38, 39]. Therefore, we exam-
ined the effects of dnVPS4A on tau phosphorylation. Tau
phosphorylation at residue S396 was significantly in-
creased by 56% with dnVPS4A (p < 0.05; Fig. 6a and b),
suggesting increased activation of GSK3β and increased
GSK3β dependent phosphorylation of tau caused by dys-
functional ESCRT dependent MVBs. Immunofluorescence
microscopy revealed increased GSK3β labelling of cells
upon dnVPS4A transfection (Additional file 10: Figure
S9A), although changes in total GSK3β or phosphorylated
GSK3α/β (S21/9) levels were not detected by Western blot
in cell lysates of Swe N2a cells transfected with dnVPS4A
(Additional file 10: Figure S9B). One possible explanation
for this apparent discrepancy is that the active GSK3β in
the cytosol and early endosomes (facing the cytosol) is
easier to visualize with immunofluorescence than the se-
questered GSK3β inside the ILVs of MVBs.
Autophagy induction partially rescues the intracellular
accumulation of Aβ
Since autophagic organelles are markedly increased in
AD and autophagy is thought to be impaired in the dis-
ease [14], we next examined LC3β-II and p62, markers
of autophagy, in dnVPS4A transfected cells accumulat-
ing intracellular Aβ. Expression of dnVPS4A in Swe N2a
cells showed increased levels of LC3β-II, which correlate
with increased numbers of autophagosomes in the cell,
by 35% (p < 0.05, Fig. 7a) and increased levels of p62 by
52% (p < 0.05, Fig. 7b). Inducing autophagy by 1 μM
Rapamycin (p < 0.01, Fig. 7c), 250 nM Torin1 or starva-
tion (Fig. 7d) reduced the dnVPS4A-induced increase in
intracellular Aβ. Thus, in the setting of dysfunctional
MVBs with Aβ that is inefficiently trafficked to
(See figure on previous page.)
Fig. 4 DnVPS4A causes increased accumulation and reduced secretion of Aβ42. Expression of control plasmid (ctr), wtVPS4A (wtVPS4) or the ATP
hydrolysis deficient mutant dnVPS4A (dnVPS4) in Swe N2a cells (A-H) or wt primary mouse neurons (I) for 24 h. a Representative Western blot of APP,
SDS-stable oligomeric Aβ species, β-CTFs and monomeric Aβ in cell lysate probed with antibody 6E10, and β-actin for protein normalization.
b Western blot analysis of full length APP, β-CTFs and α-CTFs in cell lysate probed with the C-terminal specific APP antibody 369. c Western blot
analysis of secreted αAPP (sAPPα) and Aβ in cell medium with antibody 6E10. d Densitometric quantification of A and C demonstrates that expression
of dnVPS4, but not wtVPS4, increases intracellular Aβ compared to ctr. On the other hand, both wtVPS4A and dnVPS4A reduces secreted Aβ compared to
ctr, although to a greater extent with dnVPS4A. DnVPS4 increases both cellular and secreted APP. Values are normalized against actin and
expressed as percentage of control, n > 3; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. e Cellular full length APP is increased in
cells transfected with dnVPS4A-FLAG (lower panel) compared to control plasmid Ctr-FLAG (upper panel). Scale bar 25 μm. f Antibody OC labelling of
fibrillar oligomers and fibrils is increased in cells transfected with dnVPS4A (arrows) compared to control plasmid. Scale bar 25 μm. g Antibody OC
labelling in dnVPS4-transfected cells is associated with enlarged vesicles positive for flotillin-1. Scale bar 15 μm. h Aβ42 accumulation in vesicles positive
for ESCRT protein Tsg101 in dnVPS4A-transfected cells. Scale bar 25 μm. i Wt primary neurons at 12 DIV transfected with synapsin-dnVPS4A-FLAG or
control synapsin-GFP plasmid for 24 h, immunolabelled for Aβ42 and the post-synaptic protein drebrin shows that Aβ42 labelling is increased with
expression of dnVPS4A but not with control plasmid. Scale bar 50 μm
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lysosomes for degradation and/or inefficiently secreted,
stimulation of autophagy is associated with decreased
cellular Aβ.
Discussion
Over the past years, the view of the role of Aβ in the
pathogenesis of AD has been changing. Rather than
merely aggregation of extracellular Aβ, a complex and in-
terrelated biology of intra- and extra-cellular pools of Aβ
has emerged. Progressive intraneuronal Aβ accumulation
and impaired secretion of Aβ were reported in AD trans-
genic neurons with time in culture [9, 40] and plaque-
independent, Aβ-dependent synapse damage and memory
impairment correlated with this intracellular pool of Aβ
but not plaques in AD-transgenic mice [41]. Our working
hypothesis is that dystrophic neurites with accumulat-
ing intraneuronal Aβ, initially within MVBs, are a
nidus of plaque formation [10], with an important
contribution of secreted Aβ originating also from
hyperactive neurons.
a b
Fig. 6 Blocking ESCRT dependent ILV formation increases tau phosphorylation at serine 369 (S396). a Western blot of transfected N2a Swe cells
demonstrates increased tau phosphorylation at S396 with expression of dnVPS4A. b Quantification of A shows a 56% increase in levels tau
phosphorylated at S396 with dnVPS4A; values are normalized against actin and expressed as percentage of ctrGFP, (n = 5, *p < 0.05)
c d
a b
Fig. 5 Increased cellular levels of Aβ with dnVPS4A expression is consistent with decreased lysosomal degradation. a Bafilomycin A1 (BafA1)
treatment had similar effects on Aβ as dnVPS4a, markedly increasing intracellular levels of Aβ and reducing Aβ secretion. Representative
Western blot analysis of cell lysates and cell medium from Swe N2a cells treated with 5 nM BafA1 for 24 h and blotted for 6E10 for Aβ and
β-actin. b Densitometric quantification of A. Values are normalized against actin and expressed as percentage of untreated control, n = 3, ***
p < 0.001. c When the ability of lysosomes to degrade Aβ is abolished by BafA1, blocking Aβ on route to the lysosomes via dnVPS4 does not
lead to further Aβ accumulation. Representative Western blots are shown of lysates (left) and medium (right) from Swe N2a cells treated with
5 nM BafA1 6 h after transfection with mock (no plasmid), control plasmid ctrGFP, wtVPS4A or dnVPS4A. Cells were collected 24 h post-
transfection, n = 3. d Western blot analysis of isolated exosomes secreted from Swe N2a cells transfected with mock (no plasmid), ctrGFP,
wtVPS4 or dnVPS4 for 48 h. Representative blots demonstrate that exosome secretion is not reduced with dnVPS4. Instead, increased amounts
of CD63, an exosomal marker postulated to be involved in ESCRT independent ILV formation, is seen in the exosomal fraction from dnVPS4
transfected cells. Flotillin-1, an exosomal marker associated with cholesterol-enriched lipid rafts is also increased in the exosomal fraction from
dnVPS4 transfected cells, while the ESCRT-I protein and exosomal marker Tsg101 is not changed, n = 3
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Fig. 7 (See legend on next page.)
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Here we provide novel molecular insights into endoso-
mal alterations with AD pathogenesis. Enlarged endo-
somes have been observed to be among the earliest
cellular changes in AD and the related AD pathology that
develops in Down syndrome [12]. It has been reported
that the enlarged phenotype in early endosomes and lyso-
somes in AD is independent of Aβ and instead only
dependent on APP β-CTFs [42, 43]. We now provide evi-
dence that MVB size is increased in AD transgenic neu-
rons, and that this phenotype of increased late endosomal
size can be recapitulated in wt neurons with addition of
exogenous Aβ. These data support that Aβ can induce
endosomal enlargement, but do not exclude an important
role also for APP β-CTFs. Although we only measured the
size of MVBs with EM, it is likely that also other endocytic
compartments including lysosomes and early endosomes
were affected. The large LAMP1-positive vesicles seen
and measured on confocal images (Fig. 1f) with Aβ treat-
ment, likely also include lysosomes and autolysosomes.
We show by EM fibrillar-like structures inside abnormal
MVBs/late endocytic/lysosomal compartments in neurons
treated with Aβ1-42, and immunofluorescent labelling fur-
ther indicates that MVBs/late endocytic compartments
contain aggregated Aβ1-42. We cannot fully exclude the
possibility that these aggregates begin to form in the cell
culture medium and then are taken up by the cells. How-
ever, the acidic pH environment and high peptide concen-
tration in a limited space promote amyloid aggregation
[44], a milieu that is found inside MVBs. In line with this, it
was shown in SHSY5Y cells that synthetic Aβ1-42 added to
cell culture medium at 1 μM was taken up and formed ag-
gregates of Aβ inside these cells, while only monomers
could be found in the cell culture medium even after 5 days
[45]. Overall, these results are consistent with the notion
that aggregation of Aβ1-42 is promoted inside acidic endo-
cytic compartments. Friedrich et al. (2010) [46] demon-
strated in a macrophage cell line, bundles of Aβ1-40 fibrils
in MVBs that penetrated the MVB membrane and leaked
into the cytoplasm. We now present the first experimental
evidence of Aβ42 aggregates developing inside MVBs/late
endocytic/lysosomal compartments of cultured neurons.
We also found evidence of loss of endolysosomal imper-
meability with Aβ1-42 treatment of neurons, in line with
reports in non-neuronal cells [47]. Further, we show that
Aβ fibrillar oligomers/fibrils are visible inside neurons in a
vesicular pattern as early as 45 min after addition of Aβ1-
42 to the cell medium, that are not seen when only labelling
the cell surface. Remarkably, at later time points intracellu-
lar aggregates are larger and extend into elongated struc-
tures that appear to penetrate the plasma membrane or are
potentially even secreted or extruded into the extracellular
space. Of note, the part of the elongated OC antibody posi-
tive structures that developed with time and no longer co-
labeled with the human Aβ specific antibody, might repre-
sent (1) Aβ where the N-terminal antibody binding sites be-
come inaccessible to the antibody, (2) endogenous mouse
Aβ aggregation and/or (3) incorporation of other amyloido-
genic proteins. We demonstrate the ESCRT proteins
VPS4A and Tsg101 in plaques of two different AD trans-
genic mouse models. Moreover, these ESCRT proteins
strongly colocalized with a neuronal specific marker of the
endo-lysosomal pathway, indicating the neuronal origin of
the ESCRT proteins in plaques. Previously the lysosomal
hydrolases cathepsin D and β-hexosaminidase A were
shown to colocalize with Aβ in a subgroup of diffuse pla-
ques of AD and DS patients [48] consistent with an endo-
lysosomal origin of aggregated Aβ. However, whether these
lysosomal proteins were derived from glial cells or neurons
was not determined in that study.
Expression of VPS4 mutants deficient in ATP hydroly-
sis, such as the dominant negative VPS4 E228Q used in
this study, leads to enlarged vesicles defined as a class E
phenotype, resulting from disruption of ESCRT-III re-
cycling [49–51]. VPS4 acts after the membrane scission
step to recycle ESCRT-III proteins back to monomers,
so that they are available to start a second wave of ILV
formation [52]. One might speculate that Aβ disturbs
this recycling leading to enlarged endocytic vesicles.
We show that inhibition of the late ESCRT machinery
component VPS4A mimics AD pathogenesis by causing a
marked increase in intracellular accumulation of Aβ and a
concomitant decrease in secreted Aβ, consistent with what
was reported in cultures of AD-transgenic compared to wt
neurons [40]. Choy et al., 2012, reported that depletion of
Hrs and Tsg101 in HEK293 cells stably expressing APP695
reduced Aβ secretion [53] and Edgar et al. (2015) found re-
duced Aβ40 secretion and increased intracellular Aβ when
depleting APP overexpressing N2a cells of Hrs or Tsg101
(See figure on previous page.)
Fig. 7 Induction of autophagy partially rescues dnVPS4A induced intracellular accumulation of Aβ. a Expression of dnVPS4A increases levels of LC3β-II,
an indicator of autophagy, by 35% (n = 3, *p < 0.05). Representative blot (above) and quantification (below); values are normalized against actin and
expressed as percentage of ctrGFP. b dnVPS4A increases levels of p62, an indicator of autophagy, by 52% (n = 3, **p < 0.01). Representative blot
(above) and quantification (below); values are normalized against actin and expressed as percentage of ctrGFP. c Chemically induced autophagy by
Rapamycin partially rescues the increase in intracellular Aβ from dnVPS4A. 6 h after transfection Swe N2a cells were treated with 1 μM Rapamycin and
harvested 24 h post-transfection. Representative blot (above) and quantification (below) demonstrating 35% reduction in intracellular Aβ by Rapamycin
on dnVPS4 transfected cells. Values are normalized against actin and expressed as percentage of dnVPS4 (n = 6, **p < 0.01). d Induced autophagy by
torin 1 or by starvation significantly reduces intracellular Aβ to levels in dnVPS4 transfected cells. Values are normalized against actin and expressed as
percentage of control transfected cells (n = 3, *p < 0.05, **p < 0.01)
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[54], consistent with a role for the ESCRT machinery in
preventing intracellular Aβ accumulation. However, in con-
trast to reduced Aβ secretion on depletion of early ESCRTs,
Choy et al. found increased Aβ40 secretion upon VPS4A
depletion with siRNA [53]. The difference with our demon-
stration of reduced Aβ secretion upon expression of
dnVPS4 might be explained by the different cell types and
methods of altering VPS4A that were used.
We provide evidence that the reduced secretion of Aβ
with dnVPS4 was not due to reduced exosome secretion,
since total exosome secretion was increased with
dnVPS4A. Multiple mechanisms of ILV formation have
been identified, but the relationship between different pop-
ulations of ILVs and MVBs remains unclear. Both ESCRT-
dependent and ESCRT-independent mechanisms of MVB
biogenesis exist in mammalian cells. A competitive rela-
tionship between ESCRT-dependent and -independent
mechanisms of ILV formation within single MVBs has
been suggested, with upregulation of CD63-dependent ILV
formation from ESCRT depletion [33–35]. It was shown in
HeLa-CIITA-OVA cells that depletion of VPS4B increased
the secretion of CD63 positive exosomes [55], in line with
our results of increased amounts of CD63 positive exo-
somes with dnVPS4A. It is interesting to note that in our
EM data from APP/PS1 neurons and in wt neurons treated
with Aβ1-42, we saw both enlarged MVBs with many ILVs
as well as enlarged MVBs with few ILVs. One can speculate
that these might represent two different subsets of MVBs;
it is possible that ESCRT-dependent ILV formation is dis-
turbed by Aβ/APP, resulting in enlarged and empty MVBs,
and potentially subsequent up-regulation of CD63
dependent ILVs formation resulting in MVBs filled with
many ILVs. Others have reported that formation of ILVs
destined for exosomal release was not ESCRT dependent,
while ESCRTs were necessary for ILVs destined for degrad-
ation in the lysosome [56].
The intraneuronal pool of Aβ can have a dual origin,
namely the production of Aβ from APP inside neurons
and uptake of Aβ from the extracellular space that is se-
creted by other cells and/or the same neuron. Although
we saw a net increase in intracellular Aβ levels with the
expression of dnVPS4A supporting impaired degrad-
ation of Aβ and APP, we can not rule out that the pro-
duction of Aβ from APP inside neurons was unaffected.
In the OC antibody positive dnVPS4A-transfected cells,
the enlarged vesicles also colocalized with increased la-
belling of flotillin-1 (Fig. 4g), hence associating with
cholesterol-enriched lipid microdomains. Interestingly,
ATPase-defective mammalian VPS4 was reported to
localize to aberrant late endosomes accumulating choles-
terol, due to impaired cholesterol trafficking [50] and re-
tention of cholesterol in late endosomal/lysosomal
compartments was reported to be associated with alter-
ations in APP processing [57].
Our data also demonstrate that defective MVBs, mod-
elled by dnVPS4A, leads to increased tau phosphoryl-
ation at serine 396 (S396). This site is phosphorylated by
GSK3β; hence the increased tau phosphorylation could
be due to impaired GSK3β sequestration into MVBs. Im-
munofluorescent labelling of GSK3β was increased with
dnVPS4A (Additional file 10: Figure S9A), although total
levels of GSK3β or GSK3α/β phosphorylated at serine
21/9 were not changed by Western blot. Hence, we can-
not fully conclude that defective sequestration of GSK3β
into MVBs is responsible for the increased levels of tau
phosphorylation that we see with dnVPS4. However,
consistent with our results, Tg APP-V7171 mice with the
London mutation were found to have increased phos-
phorylation of tau at S396 and increased GSK3β activity,
but no change in total levels of GSK3β and GSK3β phos-
phorylated at serine 9 [58].
We show that Aβ aggregation can initiate inside nerve
cells from vesicular accumulation of Aβ. Aberrant endo-
somal trafficking has been linked genetically and bio-
logically to a number of neurodegenerative diseases.
Proteins involved in endocytosis are also prominent
among genes linked to AD [11]. Interestingly, CD2AP,
which is genetically linked to late onset AD and has
been reported to affect MVB biogenesis and ILV forma-
tion [59], was recently reported to elevate levels of intra-
cellular Aβ in dendrites [60]. While the ESCRT-III
protein CHMP2B was first genetically linked to FTD
[23], copy number variation in CHMP2B has since been
reported in a family with familial Alzheimer’s disease
[24] and genome-wide association studies for late onset
AD identified an association with VPS4B [25]. Moreover,
immunoreactivity for CHMP2B is increased in neurons
of hippocampus in another characteristic neuropathol-
ogy of AD, granulovacuolar degeneration (GVD) [61].
CHMP2B-positive GVDs were reported to colocalize to
a greater extent with the late endosomal/lysosomal
marker LAMP1 than to the lysosomal marker cathepsin
D or to the autophagic markers LC3 and p62, suggesting
a late endosomal origin of GVDs or that they accumu-
late at the nexus of autophagic and endocytic pathways
[62]. It is interesting to note that we found CHMP2B
immunoreactivity particularly in hippocampus and med-
ial temporal lobe of 3-month-old Tg19959 mice before
plaque pathology, the two areas that are the first to have
GVD-affected neurons in AD [63].
Conclusions
Neuropathological studies have pointed to an early and ab-
errant accumulation and aggregation of Aβ within neurons
in AD, in particular in dystrophic neurites. Cell biological
studies that model this aggregation in neurons are valuable
in delineating the molecular mechanisms of Aβ-related syn-
aptic dysfunction. We propose a model where elevated
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levels of Aβ42 cause enlarged and defective MVBs, possibly
via effects on ESCRT-III components. Alternatively, MVB
dysfunction, as modelled by the expression of dnVPS4A,
can lead to accumulation of Aβ in enlarged endocytic com-
partments. These results support a scenario where distur-
bances in the MVB pathway caused by Aβ42, or vice versa,
could turn into a vicious cycle where more Aβ42 accumu-
lates and oligomeric and fibrillar aggregates form. Our find-
ings that ESCRT components colocalize with Aβ42 in
amyloid plaques in two different mouse models of AD sup-
port the scenario that aggregated Aβ42 in MVBs/late endo-
cytic compartments, potentially together with ESCRT-
components could serve as seeds for plaques.
Additional files
Additional file 1: Table S1. List of antibodies. (PDF 35 kb)
Additional file 2: Figure S1. (A) EM image of an enlarged MVB in wt
neurons treated with Aβ1-42. This image shows an example of an en-
larged MVB with very few ILVs. (B) Confocal analysis of changes in size of
LAMP1-positive structures in Aβ1-42 treated wt primary neurons with
time. Scale bar 40 μm. (PDF 8949 kb)
Additional file 3: Figure S2. (A) Confocal analysis of wt primary neurons
show that untreated (DMSO) cells have no OC labelling, while cells
incubated with Aβ1-40 for 48 h have low levels of OC labelling. However,
cells incubated with Aβ1-42 display very strong OC labelling. (PDF 4679 kb)
Additional file 4: Figure S3. (A) The early relatively weak OC labelling at
45 min of Aβ1-42 treatment colocalizes with LAMP1 labelling in the neurites,
but not with the large LAMP1-positive structures in the cell soma. Confocal
analysis of wt primary neurons treated with Aβ1-42 for 45 min. Scale 20 μm.
(B) After 48 h of Aβ1-42 treatment, OC labelling is stronger and colocalizes
partly with LAMP1-positive structures that appear enlarged and irregular in
their shape. Elongated OC-positive structures extend out from such punc-
tate LAMP1 labelling in the neuronal processes. Scale 20 μm. (C) At high
magnification, antibody OC labelling can be seen colocalizing with the late
endocytic marker Rab7 in neuronal processes of wt neurons treated for 24 h
with Aβ1-42. Scale bar 5 μm. (PDF 269 kb)
Additional file 5: Figure S4. ESCRT proteins in primary neurons and
plaques. (A-B) In young 3-month-old Tg19959 mice, CHMP2B immunolabelling
is increased in areas of hippocampus (a) and entorhinal cortex (b) that also
have increased labelling of APP/Aβ (6E10). Scale bar 40 μm, n = 4. (C) Western
blot analysis of APP/PS1 compared to wt primary neurons at 12 DIV lysed in
6% SDS shows that protein levels of CHMP2B and VPS4 are not significantly
changed, although there is a trend for increased levels of CHMP2B in APP/PS1
neurons, n > 6. Protein levels are expressed as percentage of control and are
corrected against actin. (D) VPS4 colocalizes with Aβ42 in a vesicular pattern in
19-month-old wt mice (upper panel), n = 3. In 19-month-old APP/PS1 mice
VPS4 accumulates in and around amyloid plaques (lower panel, white arrows).
Scale bar 40 μm, n = 4. (E) Decreased labelling of CHMP2B in plaques (white ar-
rows) in 19-month-old APP/PS1 mice. Some colocalization of CHMP2B is seen
in Aβ/APP (6E10) positive cells (grey arrows). Scale bar 40 μm, n = 3. (F) Label-
ling of early ESCRT-0 component Hrs is decreased in amyloid plaques compared
to surrounding brain parenchyma. Scale bar 40 μm, n = 2. (PDF 13619 kb)
Additional file 6: Figure S5. Aβ1-42 increases the diameter of LAMP-1
positive vesicles in N2a cells. Confocal images of exogenously added mono-
meric Aβ1-42 incubated for different time points, ranging from 15 min to
48 h, in N2a cells. 3D-rendering with Imaris from confocal z-stack. Colocaliza-
tion of OC labelling and LAMP1 labelling can be seen from 45 min of Aβ
treatment. The last image is from a single focal plane showing OC labelling
inside an enlarged LAMP1-positive structure as well as OC labelling that ap-
pears to localize at the cell surface. Scale bar 10 μm. (PDF 375 kb)
Additional file 7: Figure S6. DnVPS4A increases secretion but does not
change levels of intracellular α-syn. (A) Western blot analysis of α-syn N2a
cells transfected with dnVPS4A shows increased levels of extracellular α-
synuclein without altering the total pool of intracellular α-synuclein. (B)
Quantification of A. Values are normalized against actin and expressed as
percentage of control, n = 3; *p < 0.05, **p < 0.01. (C) Overexposed WB
membrane for secreted α-synuclein (same as above) with increased in-
tensity to better visualize the bands. (PDF 1607 kb)
Additional file 8: Figure S7. (A) Western blot analysis of APP and Aβ in
Swe N2a cells treated with 40 μg/ml cycloheximide (CHX) at different
times in hours (h) before harvest. Cell culture media was replaced with
fresh media 24 h before harvest. For quantification, values are normalized
against actin and expressed as percentage of control, n = 3; *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 (ANOVA with Dunnett’s multiple
comparisons test, compared to ctr). (B) Confocal images of 6E10 and
Golgi marker GM130 in Swe N2a cells treated with 40 μg/ml CHX for the
depicted times. (PDF 2263 kb)
Additional file 9: Figure S8. (A) Western blot analysis of APP and Aβ in
Swe N2a cells treated with 5 nM bafilomycin A1 (BafA1) at different time
points (h) before harvest. Cell culture media was replaced with fresh
media 24 h before harvest. (B) Quantification of A. Values are normalized
against actin and expressed as percentage of control, n = 3; *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 (ANOVA with Dunnett’s multiple
comparisons test, compared to ctr). (C) Confocal images of 6E10 and
LAMP1 labelling in Swe N2a cells treated with 5 nM bafilomycin A1 for
the depicted times. At 24 h there is a build up of both 6E10 labelling and
punctate LAMP1-positive structures. (D) Western blot analysis of APP and
Aβ in Swe N2a cells treated with 5 nM bafilomycin A1 (BafA1) 24 h be-
fore harvest and 40 μg/ml cycloheximide (CHX) at different time points
(h) before harvest. Cell culture media was replaced with fresh media 24 h
before harvest, before the addition of Baf A1. (PDF 1310 kb)
Additional file 10: Figure S9. (A) 3D images show increased GSK3β
labelling in dnVPS4-expressing N2a Swe compared to cells transfected
with control plasmid. Rab7 labelling is also increased in dnVPS4 express-
ing cells. Scale bar 15 μm. (B) Western blot analysis of cell lysates of Swe
N2a cells transfected with dnVPS4A showing no changes in total GSK3β
or phosphorylated GSK3α/β (serine 21/9). (PDF 5570 kb)
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